Einzeltreffer — DigiBib

Background: Patients with sporadic cerebral amyloid angiopathy (sCAA) frequently report cognitive or neuropsychiatric symptoms. The aim of this study is to investigate whether in patients with sCAA, cognitive impairment and neuropsychiatric symptoms are associated with a cerebrospinal fluid (CSF) biomarker profile associated with Alzheimer's disease (AD).

Methods: In this cross-sectional study, we included participants with sCAA and dementia- and stroke-free, age- and sex-matched controls, who underwent a lumbar puncture, brain MRI, cognitive assessments, and self-administered and informant-based-questionnaires on neuropsychiatric symptoms. CSF phosphorylated tau, total tau and Aβ42 levels were used to divide sCAA patients in two groups: CAA with (CAA-AD+) or without a CSF biomarker profile associated with AD (CAA-AD-). Performance on global cognition, specific cognitive domains (episodic memory, working memory, processing speed, verbal fluency, visuoconstruction, and executive functioning), presence and severity of neuropsychiatric symptoms, were compared between groups.

Results: sCAA-AD+ (n=31; mean age: 72 ± 6; 42%, 61% female) and sCAA-AD- (n=23; 70 ± 5; 42% female) participants did not differ with respect to global cognition or type of affected cognitive domain(s). The number or severity of neuropsychiatric symptoms also did not differ between sCAA-AD+ and sCAA-AD- participants. These results did not change after exclusion of patients without prior ICH.

Conclusions: In participants with sCAA, a CSF biomarker profile associated with AD does not impact global cognition or specific cognitive domains, or the presence of neuropsychiatric symptoms.

Titel:	The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.
Autor/in / Beteiligte Person:	De Kort, AM ; Kaushik, K ; Kuiperij, HB ; Jäkel, L ; Li, H ; Tuladhar, AM ; Terwindt, GM ; Wermer, MJH ; Claassen, JAHR ; Klijn, CJM ; Verbeek, MM ; Kessels, RPC ; Schreuder, FHBM
Link:	Full Text Finder (Volltext)
Zeitschrift:	Alzheimer's research & therapy, Jg. 16 (2024-05-04), Heft 1, S. 99
Veröffentlichung:	[London] : BioMed Central Ltd., 2024
Medientyp:	academicJournal
ISSN:	1758-9193 (electronic)
DOI:	10.1186/s13195-024-01454-3
Schlagwort:	Humans Female Male Aged Cross-Sectional Studies Cognitive Dysfunction cerebrospinal fluid Cognitive Dysfunction etiology Peptide Fragments cerebrospinal fluid Cognition physiology Middle Aged Magnetic Resonance Imaging Alzheimer Disease cerebrospinal fluid Alzheimer Disease complications Alzheimer Disease diagnostic imaging Cerebral Amyloid Angiopathy cerebrospinal fluid Cerebral Amyloid Angiopathy complications Cerebral Amyloid Angiopathy diagnostic imaging Amyloid beta-Peptides cerebrospinal fluid Biomarkers cerebrospinal fluid tau Proteins cerebrospinal fluid Neuropsychological Tests
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Alzheimers Res Ther] 2024 May 04; Vol. 16 (1), pp. 99. <i>Date of Electronic Publication: </i>2024 May 04. MeSH Terms: Alzheimer Disease* / cerebrospinal fluid ; Alzheimer Disease* / complications ; Alzheimer Disease* / diagnostic imaging ; Cerebral Amyloid Angiopathy* / cerebrospinal fluid ; Cerebral Amyloid Angiopathy* / complications ; Cerebral Amyloid Angiopathy* / diagnostic imaging ; Amyloid beta-Peptides* / cerebrospinal fluid ; Biomarkers* / cerebrospinal fluid ; tau Proteins* / cerebrospinal fluid ; Neuropsychological Tests* ; Humans ; Female ; Male ; Aged ; Cross-Sectional Studies ; Cognitive Dysfunction / cerebrospinal fluid ; Cognitive Dysfunction / etiology ; Peptide Fragments / cerebrospinal fluid ; Cognition / physiology ; Middle Aged ; Magnetic Resonance Imaging References: Neurology. 2019 Apr 2;92(14):e1567-e1579. (PMID: 30842300) ; Stroke. 2016 Aug;47(8):2010-6. (PMID: 27338926) ; JAMA Psychiatry. 2022 Apr 01;79(4):359-367. (PMID: 35171235) ; AJR Am J Roentgenol. 1987 Aug;149(2):351-6. (PMID: 3496763) ; Stroke. 2022 Feb;53(2):552-557. (PMID: 34538086) ; J Nucl Med. 2009 Dec;50(12):1969-74. (PMID: 19910418) ; Neurology. 2015 Dec 1;85(22):1930-6. (PMID: 26537052) ; Neuroimage. 2021 Aug 15;237:118175. (PMID: 34000407) ; Front Psychol. 2016 Oct 20;7:1601. (PMID: 27812340) ; J Geriatr Psychiatry Neurol. 2009 Jun;22(2):103-9. (PMID: 19417219) ; Ageing Res Rev. 2015 Nov;24(Pt B):232-62. (PMID: 26318058) ; Alzheimers Dement (Amst). 2021 Apr 01;13(1):e12031. (PMID: 33816750) ; Neuroimage. 2016 Dec;143:235-249. (PMID: 27612647) ; J Alzheimers Dis. 2016 Mar 8;52(1):171-8. (PMID: 27060947) ; Alzheimers Dement. 2018 Apr;14(4):535-562. (PMID: 29653606) ; Lancet Neurol. 2013 Aug;12(8):822-38. (PMID: 23867200) ; J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9. (PMID: 1627973) ; Neurology. 2018 May 15;90(20):e1751-e1758. (PMID: 29678935) ; Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12132. (PMID: 33614897) ; Ann Neurol. 2023 Jun;93(6):1173-1186. (PMID: 36707720) ; EMBO Mol Med. 2016 Jun 01;8(6):595-608. (PMID: 27025652) ; J Alzheimers Dis. 2022;87(2):791-802. (PMID: 35367960) ; JAMA Neurol. 2016 Aug 1;73(8):994-1001. (PMID: 27366898) ; Neurology. 2021 Apr 13;96(15):e1975-e1986. (PMID: 33627498) ; Alzheimers Dement. 2023 Oct;19(10):4498-4506. (PMID: 35142047) ; J Alzheimers Dis. 2015;47(2):421-32. (PMID: 26401564) ; Neurology. 2010 Apr 27;74(17):1346-50. (PMID: 20421578) ; Neurology. 1994 Dec;44(12):2308-14. (PMID: 7991117) ; J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019) ; Brain. 2015 Jan;138(Pt 1):179-88. (PMID: 25367025) ; Neurology. 2009 Nov 24;73(21):1759-66. (PMID: 19933977) ; Neurology. 2020 Jul 7;95(1):e46-e58. (PMID: 32522798) ; Stroke. 2022 Jun;53(6):1944-1953. (PMID: 35264008) ; J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):232-237. (PMID: 34728587) ; Hum Brain Mapp. 2017 Jul;38(7):3723-3731. (PMID: 28462514) ; Neurobiol Aging. 2015 Oct;36(10):2702-8. (PMID: 26239176) ; J Am Heart Assoc. 2021 Nov 16;10(22):e022089. (PMID: 34755541) ; Curr Opin Neurol. 2018 Feb;31(1):28-35. (PMID: 29120920) ; Alzheimers Dement. 2022 Jan;18(1):10-28. (PMID: 34057813) ; J Alzheimers Dis. 2011;25(1):163-73. (PMID: 21368379) ; Alzheimers Res Ther. 2021 Apr 20;13(1):84. (PMID: 33879243) ; J Clin Exp Neuropsychol. 2012;34(6):598-605. (PMID: 22384819) ; J Clin Med. 2022 Jul 13;11(14):. (PMID: 35887823) ; J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9. (PMID: 11001602) Grant Information: 733050822 Netherlands ZONMW_ ZonMw; 733050822 Netherlands ZONMW_ ZonMw; 733050822 Netherlands ZONMW_ ZonMw; 5R01NS104147-02 United States NH NIH HHS Substance Nomenclature: 0 (Amyloid beta-Peptides) ; 0 (Biomarkers) ; 0 (tau Proteins) ; 0 (Peptide Fragments) ; 0 (amyloid beta-protein (1-42)) Entry Date(s): Date Created: 20240504 Date Completed: 20240504 Latest Revision: 20240507 Update Code: 20240507 PubMed Central ID: PMC11069247

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.